Artificial intelligence in genitourinary oncology: publication trends and systematic review.

BJU IntJun 26, 2026 (epub)
Clinical ResearchOncology (Medical)Urology

Alee Kim, Nicole A Moore, Tammy Dong et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review analyzed publication trends and randomized controlled trials (RCTs) regarding artificial intelligence (AI) in genitourinary oncology. Among 2409 articles, 1220 met inclusion criteria, with a notable increase in publications from 14 in 2013 to 362 in 2023. Four RCTs were identified, indicating AI's potential to improve diagnostic performance and operational efficiency in cancer care.

Key findings

  • Publications on AI in GU oncology increased from 14 in 2013 to 362 in 2023.
  • Four RCTs were identified, with two showing improved diagnostic performance over conventional methods.
  • AI applications were most common in prostate (n=923), renal (n=274), and urothelial (n=194) cancers.
  • Risk of bias varied across studies, primarily due to randomization issues.

Why it matters

The rapid growth of AI research in genitourinary oncology highlights its potential to enhance diagnostic accuracy and treatment planning, which could significantly impact patient outcomes. Understanding these trends is crucial for clinicians to stay informed about emerging technologies in cancer care.

Source

PubMed · PMID 42360093

Published in BJU Int. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Oncology (Medical)

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.